Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine 8 mg versus placebo in overactive bladder patients with sub-optimal response to tolterodine ER
2010-024179-18Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Fesoterodine 8 mg with Placebo (2 arms). Primary endpoint: Change in urgency urinary incontinence episodes per 24 hours. Started Mar 2011; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-024179-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024179-18.